6.23
-0.53(-7.84%)
Currency In USD
| Previous Close | 6.76 |
| Open | 6.67 |
| Day High | 6.86 |
| Day Low | 5.9 |
| 52-Week High | 6.86 |
| 52-Week Low | 1.01 |
| Volume | 5.76M |
| Average Volume | 3.08M |
| Market Cap | 1.77B |
| PE | -14.49 |
| EPS | -0.43 |
| Moving Average 50 Days | 3.29 |
| Moving Average 200 Days | 2.02 |
| Change | -0.53 |
If you invested $1000 in Erasca, Inc. (ERAS) since IPO date, it would be worth $357.43 as of January 13, 2026 at a share price of $6.23. Whereas If you bought $1000 worth of Erasca, Inc. (ERAS) shares 3 years ago, it would be worth $1,497.6 as of January 13, 2026 at a share price of $6.23.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015 during dose escalation Initial Phase 1 mo
Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, to
Erasca to Present at the 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 2:08 PM GMT
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, to